| 前收市價 | 1.8800 |
| 開市 | 1.8400 |
| 買盤 | 1.7500 x 無 |
| 賣出價 | 1.9200 x 無 |
| 今日波幅 | 1.8000 - 1.9100 |
| 52 週波幅 | 1.0300 - 2.7000 |
| 成交量 | |
| 平均成交量 | 30 |
| 市值 | 無 |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | 無 |
| 業績公佈日 | 2024年8月06日 - 2024年8月12日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
InvestorPlaceThe $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
Finding good investment opportunities in the constantly changing stock market is similar to uncovering hidden treasures. Certain cheap stocks to buy are particularly noteworthy because they can yield significant gains. To begin with, using creative methods to solve unmet medical needs in cancer, the first one has become a leader in the biotechnology industry. The company’s lead product can potentially improve cancer patients’ therapy results by targeting pathways linked to tumor development and
ZacksBiotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
ZacksRegulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
